About Michael Lanuti, MD

After receiving a Bachelor of Science in BioEngineering from the University of Pennsylvania, Dr. Lanuti received his M.D. degree from the University of Pennsylvania School of Medicine . He completed his internship and residency in Surgery at the Hospital of the University of Pennsylvania and a two year research fellowship in a Thoracic Oncology Laboratory focusing on gene therapy for lung cancer. He continued with sub-specialty training, and finished a Cardiothoracic Fellowship at the Massachusetts General Hospital. He was recruited in 2004 to the staff of the Division of Thoracic Surgery, and holds a parallel appointment as Associate Professor of Surgery at Harvard Medical School. He has been the Friedman-Lambert Scholar in Academic Thoracic Surgery at MGH/HMS since 2004.  He is the Director of Thoracic Oncology for the Division of Thoracic Surgery.  Clinical interests include minimally invasive surgery for lung cancer, complex airway tumors, mediastinal tumors, esophageal cancer, navigation bronchoscopy, and surgery for hyperhidrosis. 

Clinical Interests:

Treats:

Languages:

Locations

Division of Thoracic Surgery
55 Fruit Street
Boston, MA 02114-2696
617-726-6751
Fax: 617-726-7667

Newton Wellesley Hospital
2000 Washington Street
Newton, MA 02462-1650
617-243-6447
Fax: 617-243-6449

Medical Education

  • MD, University of Pennsylvania School of Medicine
  • Residency, Hospital of the University of Pennsylvania
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Surgery, American Board of Surgery
  • Thoracic Surgery (Cardiothoracic Vascular Surgery), American Board of Thoracic Surgery

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Lanuti spearheads translational research in a Thoracic Oncology Research Laboratory. The principle goals of the laboratory are to design novel therapeutics to treat lung and esophageal cancer that can be brought to clinical trials. A primary goal is the use of oncolytic viruses to target solid tumor. Some of these strategies include development of oncolytic viruses that help degrade tumor matrix. Ultimately, this translational effort will strive to bring treatment strategies from the laboratory bench to the bedside and back to the bench again for re-evaluation and improvement.

Another lab interest is molecular imaging of pulmonary fibrosis.  We have pioneered the first collagen-PET probe to be used in the quantitation of patients carrying a diagnosis of pulmonary fibrosis. This same technology will be used to better characterize radiation induced lung injury which may ultimately be used to help differentiate lung injury from tumor recurrence.  

Stage I non small cell lung cancer can still recur with a 25% chance of relapse despite complete resection.  Dr. Lanuti is investigating the role of driver mutations and gene signatures to stratify risk of recurrence in resected stage I lung adenocarcinoma. This work can contribute to adjuvant therapies for high risk resected stage I lung cancers.

The study of epidermal growth factor and its influence on biologic functions, particularly the proliferation and differentiation of epithelial tissues, has received tremendous attention. Dr. Lanuti has investigated molecular risk factors for esophageal adenocarcinoma and found an elevated risk associated with single nucleotide polymorphisms in the epidermal growth factor (EGF) gene.

Publications

  • View my most recent publications at PubMed

    Recent Publications:

    • Costantino CL, Geller AD, Wright CD, Ott HC, Muniappan A, Mathisen DJ, Lanuti M.  Carinal surgery: A single-institution experience spanning 2 decades. J Thorac Cardiovasc Surg. 2018 Dec 15.
    • Geller, AD, Zheng H, Gaissert HA, Mathisen DJ, Muniappan A, Wright CD, Lanuti M.  Relative Incremental Cost of Postoperative Complications of Esophagectomy. Sem Thor Cardiovasc Surg. 2019 Summer;31(2):290-299.
    • Geller AD, Zheng H, Mathisen DJ, Wright CD, Lanuti M. Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018 Apr;155(4):1804-1811.
    • Désogère P, Tapias LF, Hariri LP, Rotile N, Rietz TA, Probst CK, Blasi F, Day H, Elliot J, Mino-Kenudson M, Weinreb P, Violette SM, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Trans Med. 2017 Apr 5;9(384).
    • Izar B, Sequist L, Lee M, Muzikansky A, Heist RS, Iafrate AJ, Dias-Santagata D, Mathisen DJ, Lanuti M. Impact of EGFR mutation status on outcomes in patients with resected stage I NSLC. Ann Thorac Surg. 2013 Sep;96(3):962-8.
    • Sharma A, Willers H, Digumarthy SR, Mathisen DJ, Shepard JO. Radiofrequency ablation for stage I non small cell lung cancer: management of loco-regional recurrence. Ann Thorac Surg, 2012 Mar;93(3):921-8.